Document is current

Article History

Received: 25 June 2025

Accepted: 24 September 2025

First Online: 4 November 2025

Competing interests

: C.K. reports funding paid to institution and donation of drugs to institution from Janssen for the work reported in this manuscript. S.S. reports funding paid to institution and personal fees for speaking at symposia from Janssen and donation of drugs to institution from ViiV, all outside the work reported in this manuscript. F.C. reports funding paid to institution and donation of drugs to institution from Janssen and funding paid to institution from ViiV, Gilead, Wellcome Trust and the National Institute of Health Research UK outside the work reported in this manuscript; and unpaid role as Chair of Steering Committee for an investigator-initiated long-acting implementation trial. K.M. reports personal fees for speaking at symposia from Janssen outside of the work reported in this manuscript. V.E. is an employee of Johnson and Johnson and holds stock options of Johnson and Johnson; and a patent related to rilpivirine. P.M. was an employee of Janssen at the time of trial design; and then an employee of ViiV during the time of trial conduct and manuscript submission; and holds stock from GSK as an employee of ViiV. F.A.B. was an employee of Johnson and Johnson at the time of trial design and conduct. N.I.P. reports grants paid to institution, donation of drugs to institution and personal fees for speaking at symposia from Janssen outside the work reported in this manuscript; and is the Chief Investigator on a trial with funding paid to institution by the European Union for testing anti-tuberculosis drug combinations based on the drug ganfeborole, owned by GSK. I.K.M., J.M., H.M., I.Y., A.S., J.K., R.S., L.N., K.O., C.O., M.O. and C.W. declare no competing interests.